BACKGROUND AND OBJECTIVES: Imatinib is the new standard drug treatment for patients
with chronic myelogenous leukemia (CML). Quantitative reverse transcription-polymerase …

Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the
peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to …

Survival among chronic myelogenous leukemia (CML) patients can be linked to the
reduction in leukemic cell burden. Treatment with imatinib mesylate results in a high …

Context.—Although bone marrow (BM) karyotyping has been the standard in monitoring
patients with chronic myeloid leukemia, peripheral blood (PB) monitoring methods may be …

Abstract Abstract 783 FN2 Introduction: The advent of second generation tyrosine kinase
inhibitors (TKI) in the front line treatment setting of chronic myeloid leukemia (CML) has …

Imatinib mesylate (IM) is the first line therapy against Chronic Myeloid Leukemia, effectively
prolonging overall survival. Because discontinuation of treatment is associated with relapse …

BACKGROUND AND OBJECTIVES: Imatinib induces complete cytogenetic responses
(CCR) in the majority of patients with chronic myeloid leukemia (CML) in chronic phase …

Imatinib mesylate (trade name Glivec® or Gleevec) is emerging as an important therapy in
the management of chronic myeloid leukaemia (CML). It is clinically useful to monitor the …

Background The monitoring of BCR-ABL transcript levels by real-time quantitative
polymerase chain reaction (RT-qPCR) has become important to assess minimal residual …

Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …